{"denoms":[{"counts":[{"groupId":"BG000","value":"23"}],"units":"Participants"}],"groups":[{"description":"Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.","id":"BG000","title":"Gleevec"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.2","value":"64.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"80-89 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]}],"paramType":"NUMBER","title":"FIGO (International Federation of Gynecology and Obstetrics) Stage Recurrent/Persistent","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Carcinosarcoma-homologous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Carcinosarcoma-heterologous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Carcinosarcoma, Malignant Mixed Mullerian Tumor"}],"paramType":"NUMBER","title":"Histologic Type","unitOfMeasure":"participants"}],"populationDescription":"Eligible and treated patients."}